Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: 0.29 + statin + pushes  Related to the article below (Last Update: 8/5/2008)

Effect of Simvastatin on Cognitive Functioning in Children With ...
Journal of American Medical Association (subscription), IL - Jul 15, 2008
Recently, it was shown that statin-mediated inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase restores the cognitive deficits in an NF1 mouse ...
Source: Google News

[PDF] A comparative study on the effects of niacin plus atorvastatin with that of fenofibrate plus …
S Ahmed, AKMM Hossain, SR Dey, AKM Akhtaruzzaman, … - Bangladesh Journal of Pharmacology, 2008 - banglajol.info
... therapy of statin-niacin and statin- fenofibrate on ... without any anticoagulant with
a gentle push to avoid ... 1.17 ? 0.26 1.00 ? 0.17* 1.10 ? 0.29 1.01 ? 0.15 ...
-

Haemodialysis
J Borawski, M Wilczynska-Borawska, W Stokowska - Nephrology Dialysis Transplantation - ERA-EDTA
... beta value 0.37, p<0.01), residual renal function (beta value -0.29, p<0.05 ... Recently
statin have shown anti inflammatory properties in addition to their lipid ...

High throughput HPLC method for determining Log P values -
J Abedi - US Patent 6,524,863, 2003 - freepatentsonline.com
... agent with the greater affinity to SP pushes this train ... mimic amino acid residues,
such as statin, bestatin, etc. ... uracil (1), 0.29, 0.32, 0.29, 0.29, 0.015, -1.07 ...

Pharmaceutical formulations, methods, and dosing regimens for the treatment and prevention of acute … -
CL Bisgaier, ND Lalwani, WV Rodrigueza, D Hartman, … - US Patent 20,050,142,180, 2005 - freepatentsonline.com
... for example, treatment with statins, can require ... intravenous infusions and intravenous
push infusions (?bolus ... exhibits a hydrophobicity of 0.29 according to ...
-

Counterregulation by epinephrine and glucagon during insulin-induced hypoglycemia in the conscious … -
CC Connolly, RE Ivy, BA Adkins-Marshall, RL … - Diabetes Research and Clinical Practice, 1996 - Elsevier
... which was observed when somato- statin and combined ... extraction of alanine increased
from 0.29 + 0.03 to ... partly ex- plained by a ?substrate push? phenomenon ...

Remittances and the Real Exchange Rate -
H LOPEZ, M BUSSOLO, L MOLINA - World, 2007 - papers.ssrn.com
... Output growth in the non-tradable sectors will push up factor demands, especially
for those factors used intensively in these sectors. ...

The Expanding Role for Retinoid Signaling in Heart Development
LL Hoover, EG Burton, BA Brooks, SW Kubalak - TheScientificWorldJOURNAL, 2008 - thescientificworld.com
... As the field pushes forward, it has become increasingly clear ... h,i,j 7?10 ?M
0.29?10 ?M 1.4 ... that levels of retinoids were altered in statin-treated systems ...
-

[PDF] Managing Complex Patients and Lesions with Drug-Eluting Stents -
D Kereiakes, C Rogers, DI Simon - The Official Journal of the International Andreas Gruentzig …, 2005 - invasivecardiology.com
... using more standardized testing methodology, have shown no difference in clopidogrel
platelet inhibition by randomly allocated statin treatment, whether CYP ...

[PDF] The Art of Balance
EU Rotterdam - publishing.eur.nl
... the effect of cardiac risk factors and (preventive) statin, aspirin and ... Push 4 ,
Material Requirements Planning 5 , Manufacturing Resource Planning / MRP and ...

ACC. 07 and i2 Summit Highlights: A Conversation With the Experts -
EM Tuzcu, RC Starling, JD Thomas - Journal of the American College of Cardiology, 2007 - Elsevier
... Compared with placebo, statin therapy significantly slowed progression of maximum
CIMT for 12 carotid sites (Table 3). Moreover, although there was significant ...

Source: Google Scholar

Merck pushes for over-the-counter statin in US

Last Updated: 2007-12-13 13:53:49 -0400 (Reuters Health)

By Lisa Richwine

SILVER SPRING, Md. - Making a cholesterol drug available over the counter could give millions of Americans a new option to reduce the risk of heart disease and provide a major public health benefit, drugmaker Merck & Co Inc argued to a U.S. advisory panel on Thursday.

The company is making its third bid for U.S. approval to sell a low-dose, nonprescription version of its Mevacor cholesterol-lowering pill. Mevacor is one of the statin drugs taken by millions to cut cholesterol and the risk of heart disease, the leading killer of Americans.

Moving a statin over the counter would be a major shift. Nonprescription drugs generally treat short-term conditions with easy-to-recognize symptoms such as a headache or runny nose. High cholesterol can be detected only with a blood test, and statin treatment can last years.

The Food and Drug Administration is asking an advisory panel of outside experts to consider if patients can accurately decide for themselves if they are candidates for Mevacor.

The advisory panel is expected to vote later Thursday on whether to recommend approval for nonprescription Mevacor. The FDA will make the final decision but usually follows panel recommendations. Merck said an FDA ruling is expected in the first quarter of 2008.

An estimated 20 million Americans face moderate heart-disease risk and could benefit from a statin, yet just 6 million of them are on treatment, Merck officials said.

Having Mevacor available on drugstore shelves could lure many untreated patients to therapy, said Edwin Hemwall, an official with Merck Research Laboratories.

"Over time it will reduce the risk of a first heart attack and provide a real impact on public health," Hemwall said.

In a preliminary review released before the panel meeting, FDA reviewers questioned Merck's studies of patients who read the drug's proposed label and decided if they should try Mevacor.

In one study, about 30 percent of people with diabetes or a history of heart disease or a stroke wanted to buy Mevacor, FDA reviewers said. The label advised such patients to consult a doctor before use.

GlaxoSmithKline PLC recently acquired exclusive U.S. rights to sell over-the-counter Mevacor in return for undisclosed milestone and royalty payments to Merck.

Prescription Mevacor, known generically as lovastatin, debuted on the U.S. market in 1987. The drug lost patent protection in 2001. An over-the-counter version would receive three years of exclusive marketing time before generic competition could begin.

Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.